A comparison of Health Technology Appraisal (HTA) timelines and requirements for orphan technologies in 10 European countries

Previous PostCost-effectiveness of difelikefalin for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients receiving in-centre haemodialysis